
HPV-linked throat cancer on the rise among Korean men
Park Jun-wook, a head and neck cancer specialist at the Catholic University of Korea's Seoul St. Mary's Hospital, said the rising trend underscores the importance of raising awareness about HPV-related cancers and the need for vaccination among men.
HPV is widely known as the leading cause of cervical cancer, and in Korea, the HPV vaccine has traditionally been considered a vaccine for women.
However, in recent years, medical experts have warned that HPV can also cause oropharyngeal cancer, a type of cancer that affects the upper part of the throat, especially in men. Oral sex with an HPV-infected partner has been widely considered a major route of transmission.
Recent data further supports the need for men to get vaccinated.
According to the Health Insurance Review and Assessment Service, genital warts, primarily caused by HPV, were most commonly found among men in their 20s and 30s in 2023.
That year, there were 14,146 male cases in their 20s and 19,719 in their 30s. This was approximately 4.4 times higher than the number of cases among women in the same age groups, which were 5,418 and 2,324, respectively.
HPV-related oropharyngeal cancer is also on the rise.
A 2023 report by the Korean Society of Otorhinolaryngology found that 487 men were diagnosed with HPV-caused tonsil cancer in 2019, a 2.6-fold increase from 187 cases in 2002.
Park also warned that these cancers can be difficult to detect early, as symptoms often are not immediately apparent.
'Head and neck cancers can be silent early on. If you notice a sore in your mouth that doesn't heal or a lump in your neck, you should seek medical attention promptly,' he said.
Early detection is critical to improving survival rates. According to Park, the five-year survival rate for advanced cases ranges from 50 to 60 percent, but rises to over 80 percent when the cancer is caught early.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Korea Herald
3 hours ago
- Korea Herald
2NE1's Park Bom to suspend activities
Park Bom of 2NE1 will take time off to focus on her health, her agency D-Nation Entertainment announced Wednesday. She has decided not to join the group's activities for the time being, said the agency, adding that she was told to rest and recover. She picked up her career as the main vocalist last year when the group reunited for its 15th debut anniversary. Park had a short break after the full-group concert and toured Asia until April. However, there have been voices of concern over her health. Last month, she missed out on Waterbomb Busan 2025 but proved she was alright last week at the match between Tottenham and Newcastle in Seoul, where 2NE1 performed at halftime.


Korea Herald
20 hours ago
- Korea Herald
Park Bom to step down from 2NE1 activities due to health concerns
Park Bom, a member of girl group 2NE1, will not be participating in the group's upcoming activities due to health issues, her agency announced Wednesday. 'We inform you that Park Bom will not be able to join 2NE1's future schedule,' D-Nation Entertainment said via social media. 'After receiving medical advice recommending sufficient rest and stability, we reached this decision after careful discussions.' 'We ask for your warm support for Park Bom's recovery, and we would be grateful if you could also cheer on Sandara Park, CL and Minzy, who will do their best to fill the void,' the company added. Concerns about Park's health and her ability to continue group activities have been raised in recent months. She has alarmed fans by posting heavily filtered selfies and making unverified personal claims online — including stating she is dating actor Lee Min-ho — raising questions about her health. The singer also abruptly canceled her appearance at the Waterbomb Busan festival on July 26, an unusual move in the tightly scheduled world of K-pop, where same-day cancellations are rare. Meanwhile, Park, alongside 2NE1 members, performed Saturday during the halftime show at a friendly football match between Tottenham Hotspur and Newcastle United FC at Seoul World Cup Stadium.


Korea Herald
7 days ago
- Korea Herald
Daewoong's Nabota hits record H1 sales, expands to Middle East
South Korean drugmaker Daewoong Pharmaceutical announced Thursday that its botulinum toxin product, Nabota, posted 115.4 billion won ($83 million) in revenue in the first half of this year, up 28 percent from last year. With this growth, Daewoong expects to surpass 200 billion won in annual sales this year. Nabota was approved by the US Food and Drug Administration in 2019 as the first Asian botulinum toxin. Since then, Daewoong has pursued a premium strategy focused on high purity, high safety and strict quality control standards. Nabota is now sold under the brand name Jeuveau in the US, the world's largest aesthetics toxin market, where it holds a 14 percent market share in the aesthetics segment, ranking second overall. Daewoong also continues to grow in Latin America and Southeast Asia, following major deals previously signed in Brazil and Thailand. The company recently signed a deal with Kuwait, expanding its reach to five Middle Eastern countries, including the UAE, Saudi Arabia and Qatar — the widest regional coverage among Korean toxin brands. Alongside product expansion, Daewoong is promoting its proprietary injection technique, Nabolift, through global training programs, aiming to enhance medical outcomes and brand presence. 'Nabota is now a global top-tier brand in aesthetics,' said Yoon Joon-soo, head of Daewoong Pharmaceutical's Nabota Business Division. 'We will strengthen our global leadership with premium quality and scientific proof.'